Drugs / atamparib
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04053673 | Aug 2019 → Jun 2023 | cancer | Ribon Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07374419 | Feb 2026 → Jul 2028 expected | lung adenocarcinoma | Nerviano Medical Sciences (Shanghai) Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05127590 | Mar 2022 → Nov 2023 | non-small cell squamous lung carcinoma | Ribon Therapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | atamparib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07374419 ↗ |
| Known as | ATAMPARIB (RBN-2397) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095043 ↗ |
| Known as | RBN-2397 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05127590 ↗ |
| Action | Inhibit | “RBN-2397 inhibits PARP7” NCT04053673 ↗ |
| Modality | Small molecule | — CHEMBL5095043 ↗ |
| Route | Oral | “Continuous oral dosing with the RP2D of RBN-2397 (outpatient basis).” NCT05127590 ↗ |
| Target | PARP7 | “RBN-2397 inhibits PARP7” NCT04053673 ↗ |